Comment on

• Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells.

  Qasim W. Qasim W. Blood. 2023 Feb 23;141(8):835-845. doi: 10.1182/blood.2022016204. Blood. 2023. PMID: 36223560 Free PMC article.
• Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies.

  Cichocki F, van der Stegen SJC, Miller JS. Cichocki F, et al. Blood. 2023 Feb 23;141(8):846-855. doi: 10.1182/blood.2022016205. Blood. 2023. PMID: 36327161 Free PMC article. Review.
• Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.

  Courtney AN, Tian G, Metelitsa LS. Courtney AN, et al. Blood. 2023 Feb 23;141(8):869-876. doi: 10.1182/blood.2022016201. Blood. 2023. PMID: 36347021 Free PMC article. Review.
• Allogeneic natural killer cell therapy.

  Berrien-Elliott MM, Jacobs MT, Fehniger TA. Berrien-Elliott MM, et al. Blood. 2023 Feb 23;141(8):856-868. doi: 10.1182/blood.2022016200. Blood. 2023. PMID: 36416736 Free PMC article. Review.
• Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies.

  Quach DH, Lulla P, Rooney CM. Quach DH, et al. Blood. 2023 Feb 23;141(8):877-885. doi: 10.1182/blood.2022016202. Blood. 2023. PMID: 36574622 Free PMC article.